1. | dddimensions | |
2. | alein99 | |
3. | jjhale69 | |
4. | robflutie | |
5. | jakuwladi |
1. | dddimensions | |
2. | alein99 | |
3. | jjhale69 | |
4. | robflutie | |
5. | jakuwladi |
1. | alein99 01/22/2018 $85 million of its common stock |
2. | robflutie 10/01/2017 Noble Financial resumes at Buy. When the company releases positive phase 2b results on MS study, the stock is heading up to the next level. They are trying to bore us right now... |
3. | dddimensions 10/01/2017 I think this drug has a good chance to make it. EMERYVILLE, Calif., Sept. 07, 2017-- Adamas Pharmaceuticals, Inc. today announced positive topline data from the Phase 1 b clinical trial of ADS-4101 |
4. | jjhale69 02/08/2018 Tempting! |
5. | elche7947 05/24/2018 Reports publication of PK data regarding GOCOVRI in Clinical Pharmacokinetics |
6. | dddimensions 01/22/2018 Adamas Announces Proposed Public Offering of Common Stock |
7. | rodina9046 04/04/2018 Leerink Partners initiates as an outperform, $31PT |
8. | jjhale69 01/23/2018 Anyone seen this news? PT $48 |
9. | jakuwladi 02/20/2018 No anger at all...I rest well at night... this is a long term hold for me |
10. | jakuwladi 02/22/2018 Misses EPS loss estimates by $0.09 and slightly misses on revenues |